The $150 billion bet to end Western pharma’s China dependency

The pharmaceutical supply chain ran on a single logic for thirty years: move production to wherever labor and regulation are cheapest, import the finished product, and pass the savings on. That logic held until COVID-19 disrupted shipping lanes and Asian production facilities simultaneously, and every Western government with drug shortages found itself asking the same question — how much would it cost to bring manufacturing back?

Active pharmaceutical ingredients, or APIs, are the chemical compounds that give a drug its therapeutic effect. They are made overwhelmingly in Asia. Only 9% of API manufacturers operate in the United States; China and India together control roughly 70% of global capacity. For specific drugs, the concentration is sharper: China accounts for 95% of US ibuprofen imports, 91% of hydrocortisone, and 70% of acetaminophen. India, which fills more than half of US generic prescriptions, sources up to 80% of its own APIs from China — meaning a disruption in Chinese production ripples through the supply chain that appears to diversify away from it.

Pharmaceutical reshoring is the response to that concentration risk. The term covers a range of policies and corporate decisions aimed at shifting API production and finished-drug manufacturing back to Western or allied facilities. The economic case is not cost reduction — domestic manufacturing costs more than Asian production. The case is supply security: the ability to fill a prescription during a shipping disruption, a geopolitical standoff, or a pandemic.

The legislative architecture took shape in 2025. The US BIOSECURE Act, passed as part of the National Defense Authorization Act, restricts federal procurement from specified Chinese biotech companies. The European Union’s Critical Medicines Act created a framework for Strategic Projects in EU pharmaceutical manufacturing, with access to fast-track permitting and EU funds including InvestEU and Horizon Europe. Antibiotic APIs drew particular pressure on both continents, a dynamic our earlier reporting on Sandoz’s case to Brussels traced in detail.

Industry pledges followed quickly. Eli Lilly announced $27 billion for domestic API and sterile injectable expansion. Across the sector, major pharmaceutical companies have committed nearly $150 billion in US manufacturing investments over the next decade.

The tension is structural: reshoring transfers cost rather than eliminating it. Generic drugs carry the prices they do because manufacturing moved to the cheapest available location. Bringing it back at a premium means the cost lands somewhere — in government procurement budgets, in insurance premiums, or in what patients pay. The already-contested economics of pharmaceutical pricing — the Ozempic pricing debate compressed the industry’s tensions into a single molecule — will not get simpler when domestic manufacturing adds another cost layer.

Pharmaceutical manufacturing capacity takes years to build. The political appetite to pay a premium for supply security tends to last only as long as the shortage that everyone still remembers.

Tags: BIOSECURE Act, drug manufacturing, Eli Lilly, pharmaceutical reshoring, supply chain